Treatment of dysferlinopathy with deflazacort: A double-blind, placebo-controlled clinical trial

Maggie C. Walter, Peter Reilich, Simone Thiele, Joachim Schessl, Herbert Schreiber, Karlheinz Reiners, Wolfram Kress, Clemens Müller-Reible, Matthias Vorgerd, Peter Urban, Bertold Schrank, Marcus Deschauer, Beate Schlotter-Weigel, Ralf Kohnen, Hanns Lochmüller

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

Background: Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B). Methods. We assessed the one-year-natural course of dysferlinopathy, and the safety and efficacy of deflazacort treatment in a double-blind, placebo-controlled cross-over trial. After one year of natural course without intervention, 25 patients with genetically defined dysferlinopathy were randomized to receive deflazacort and placebo for six months each (1 mg/kg/day in month one, 1 mg/kg every 2nd day during months two to six) in one of two treatment sequences. Results: During one year of natural course, muscle strength declined about 2% as measured by CIDD (Clinical Investigation of Duchenne Dystrophy) score, and 76 Newton as measured by hand-held dynamometry. Deflazacort did not improve muscle strength. In contrast, there is a trend of worsening muscle strength under deflazacort treatment, which recovers after discontinuation of the study drug. During deflazacort treatment, patients showed a broad spectrum of steroid side effects. Conclusion: Deflazacort is not an effective therapy for dysferlinopathies, and off-label use is not warranted. This is an important finding, since steroid treatment should not be administered in patients with dysferlinopathy, who may be often misdiagnosed as polymyositis. Trial registration. This clinical trial was registered at, identifier: NCT00527228, and was always freely accessible to the public.

Original languageEnglish
Article number26
JournalOrphanet Journal of Rare Diseases
Volume8
Issue number1
DOIs
StatePublished - 2013
Externally publishedYes

Keywords

  • Deflazacort
  • Dysferlinopathy
  • Limb girdle muscular dystrophy (LGMD)
  • Muscle strength
  • Steroids
  • Therapy

Fingerprint

Dive into the research topics of 'Treatment of dysferlinopathy with deflazacort: A double-blind, placebo-controlled clinical trial'. Together they form a unique fingerprint.

Cite this